Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2 Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of GS-4224 in Subjects With Advanced Solid Tumors

NCT04049617 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT04049617
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04049617 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2 Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of GS-4224 in Subjects With Advanced Solid Tumors
Lead sponsor
Gilead Sciences
Phase
Phase 1
Overall status
Terminated
Start date
August 26, 2019
Completion date
March 30, 2021
Enrollment
18 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors